Otsuka Loses Fee Bid In Abilify Patent Suit
A New Jersey federal judge has refused to order several generic drug companies to pay Otsuka Pharmaceutical Co.'s attorneys' fees in a case over schizophrenia drug Abilify, despite the Federal Circuit...To view the full article, register now.
Already a subscriber? Click here to view full article